Table 1.
Characteristics of studies included for this systematic review.
| Study | Sample Size | Regimen | Detection Methods for HBsAg and HBeAg | Treatment Duration (Weeks) | Follow-up Period (Weeks) | HBV Genotype | Interferon | ||
|---|---|---|---|---|---|---|---|---|---|
| Comb/Mono | Comb | Mono | Comb | Mono | Type | ||||
| Yuan, 2014 [9] | 26/28 | ETV 0.5 mg/d + Peg-IFNα-2a 180 μg | ETV 0.5 mg/d | AIA1800 Chemiluminescence Analyzer, TOSOH Corporation, Tokyo, Japan | 48 | 52 | unknown | unknown | Peg-IFNα-2a |
| Zeng, 2013 [10] | 20/20 | ETV 0.5 mg/d + Peg-IFNα-2a 180 μg | ETV 0.5 mg/d | i2000 electro-chemiluminescence, Abbot Diagnostic Division, Sligo, UK | 24 | unknown | unknown | unknown | Peg-IFNα-2a |
| Yu, 2013 [11] | 90/45 | Lam 100 mg + IFN-α-2b 50 μg/Adv 10 mg + IFN-α-2b 50 μg/Adv 10 mg + Peg-IFNα-2a 180 μg | Lam 100 mg/ Adv 10 mg | Enzyme immunoassay, AxSym analyzer, Abbot Diagnostic Division | 96 | 24 | unknown | unknown | IFN-α-2b/Peg-IFNα-2a |
| Li, 2013 [12] | 17/22 | Adv 10 mg + Peg-IFNα-2a 180 μg | Adv 10 mg | unknown | 48 | unknown | unknown | unknown | Peg-IFNα-2a |
| Li, 2012 [13] | 44/51 | ETV 10 mg/d + IFNα-2b | ETV 10 mg/d | Cobass601 electro-chemiluminescence, Roche, Basel and Kaiseraugst, Switzerland | 48 | unknown | unknown | unknown | IFNα-2b |
| Wang, 2012 [14] | 30/31 | Adv 10 mg + IFNα-2b 50 μg | Adv 10 mg | IMx analyzer, Abbot Diagnostic Division | 48 | 24 | unknown | unknown | IFNα-2b |
| Chen, 2012 [15] | 19/35 | ETV 0.5 mg/d + Peg-IFNα-2a 180 μg | ETV 0.5 mg/d | Architect HBsAg QT, Abbot Diagnostic Division | 72 | 72 | B 12 (63%) C 7 (37%) | unknown | Peg-IFNα-2a |
| Ding, 2010 [16] | 22/23 | Adv 10 mg + Peg-IFNα-2a 180 μg | Adv 10 mg | unknown | 48 | unknown | unknown | unknown | Peg-IFNα-2a |
| Piratvisuth, 2008 [17] | 112/112 | Lam 100 mg + Peg-IFNα-2a 180 μg | Lam 100 mg | Microparticle enzyme immunoassay (AXSYM HBe 2.0, Abbott Laboratories, Abbott Park, IL, USA) | 48 | 48 | B 30% C 32% | 43% 49% | Peg-IFNα-2a |
| Li, 2006 [18] | 31/43 | Adv 10 mg + IFNα-2b 50 μg | Adv 10 mg | Shanghai GeneCore Biotechnologies Corporation, Shanghai, China | 104 | unknown | unknown | unknown | IFNα-2b |
| Janssen, 2005 [19] | 130/136 | Lam 100 mg + Peg-IFNα-2b 100 μg/w | Lam 100 mg | EIA (AxSYM, Abbott, Abbott Park, Chicago, IL, USA). | 52 | 24 | A 43 (33%) B 11 (9%) C 18 (14%) D 52 (40%) | 47 (35%) 12 (9%) 21 (15%) 51 (38%) | Peg-IFNα-2b |
| Amarapurkar, 2005 [20] | 20/5 | Lam 100 mg + Peg-IFNα-2b 180 μg | Lam 100 mg | Versant HBV DNA 1.0 assay, Bayer Corp, NewYork, NY, USA | 48 | 24 | unknown | unknown | Peg-IFNα-2b |
| Sarin, 2005 [21] | 38/37 | Lam 100 mg + IFN-α 5 MU | Lam 100 mg | Enzyme immunoassay | 52 | 24 | unknown | unknown | IFN-α |
| Chan, 2005 [22] | 48/47 | Lam 100 mg + Peg-IFNα-2b 100 μg | Lam 100 mg | Applied Biosystems, Foster City, CA, USA | 60 | 52 | B 15 (31%) C 30 (62%) | 16 (34%) 28 (60%) | Peg-IFNα-2b |
| Lau, 2005 [23] | 271/272 | Lam 100 mg + Peg-IFNα-2a 180 μg | Lam 100 mg | Central laboratory, AxSYM test (Abbott) | 48 | 24 | A 18 (7%) B 82 (30%) C 156 (58%) D 11 (4%) | 15 (6%) 73 (27%) 162 (60%) 17 (6%) | Peg-IFNα-2a |
| Song, 2004 [24] | 60/30 | Lam 100 mg + IFNα-2b 3 MU | Lam 100 mg | 71705 Biochemical analyzer, HITACHI, Tokyo, Japan | 24 | 60 | unknown | unknown | IFNα-2b |
| Deng, 2003 [25] | 32/24 | Lam 100 mg + IFNα-2b 5 MU | Lam 100 mg | ELISA, Shanghai Kehua Bio-engineering Corporation, Shanghai, China | 48 | 24 | unknown | unknown | IFNα-2b |